ANDREWS RONALD ASBURY 4

What Happened

• Ronald Asbury Andrews, a director of Plus Therapeutics (PSTV), received three derivative awards on May 14, 2026 totaling 8,972 restricted stock units (RSUs): two grants of 3,686 RSUs and one grant of 1,600 RSUs. Each grant shows $0 paid (typical for RSU awards), so no cash purchase or sale occurred. These are awards (compensation), not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (filed four days after the transaction; Form 4s are generally required within two business days, so this appears to be later than the usual reporting window).
• Grants: 3,686 RSUs + 3,686 RSUs + 1,600 RSUs = 8,972 RSUs; reported acquisition price $0 (derivative award).
• Vesting (per footnote F1): RSUs vest ratably over four quarters in substantially equal 1/4 increments, with the first 1/4 vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
• Shares owned after the transaction: Not specified in the filing.
• Other footnotes in the filing (F2, F3) describe option vesting schedules but are not the awards reported in these specific grant lines.

Context

• These were compensation awards (RSUs), not market purchases or sales; such awards are routine for executives/directors and do not directly indicate immediate buying or selling sentiment.
• Because these are derivative awards, shares will only be received as the RSUs vest per the stated schedule.